• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

离子导入角膜交联增强光疗:3 年临床结果。

Iontophoresis Corneal Cross-linking With Enhanced Fluence and Pulsed UV-A Light: 3-Year Clinical Results.

出版信息

J Refract Surg. 2020 May 1;36(5):286-292. doi: 10.3928/1081597X-20200406-02.

DOI:10.3928/1081597X-20200406-02
PMID:32396639
Abstract

PURPOSE

To assess 3-year safety and efficacy of enhanced-fluence pulsed-light iontophoresis cross-linking (EF I-CXL) in patients with progressive keratoconus.

METHODS

This prospective interventional pilot study included 24 eyes of 20 patients, with a mean age of 23.9 years (range: 15 to 36 years). Iontophoresis with riboflavin solution was used for stromal imbibition. The treatment energy was optimized at 30% (7 J/cm) and ultraviolet-A power set at 18 mW/cm × 6.28 minutes of pulsed-light on-off exposure, with a total irradiation time of 12.56 minutes. Uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), corneal tomography, and corneal optical coherence tomography (OCT) at baseline and 1, 3, 6, 12, 24, and 3 years postoperatively were evaluated.

RESULTS

At 3 years, average UDVA decreased from 0.50 ± 0.10 to 0.36 ± 0.08 logMAR (P < .05), average maximum keratometry decreased from 52.94 ± 1.34 to 51.4 ± 1.49 diopters (D) (Delta: -1.40 ± 0.80 D; P < .05), average coma improved from 0.24 ± 0.05 to 0.12 ± 0.02 µm (P = .001), and symmetry index decreased from 4.22 ± 1.01 to 3.53 ± 0.90 D. Corneal OCT showed demarcation line detection at 285.8 ± 20.2 µm average depth in more than 80% at 1 month postoperatively.

CONCLUSIONS

The 3-year results of EF I-CXL showed satisfactory I-CXL functional outcomes, increasing the visibility and the depth of demarcation line closer to epithelium-off standard CXL. [J Refract Surg. 2020;36(5):286-292.].

摘要

目的

评估强化脉冲光离子导入交联(EF I-CXL)在进行性圆锥角膜患者中 3 年的安全性和疗效。

方法

本前瞻性干预性试点研究纳入了 20 名患者的 24 只眼,平均年龄为 23.9 岁(范围:15 至 36 岁)。使用核黄素溶液进行离子导入以实现基质浸润。优化治疗能量为 30%(7 J/cm),紫外线-A 功率设定为 18 mW/cm×6.28 分钟的脉冲光开/关照射,总辐照时间为 12.56 分钟。在基线和术后 1、3、6、12、24 和 3 年评估未矫正距离视力(UDVA)、矫正距离视力(CDVA)、角膜地形图和角膜光学相干断层扫描(OCT)。

结果

3 年后,平均 UDVA 从 0.50±0.10 降至 0.36±0.08 logMAR(P<.05),平均最大角膜曲率从 52.94±1.34 降至 51.4±1.49 屈光度(D)(差值:-1.40±0.80 D;P<.05),平均彗差从 0.24±0.05 改善至 0.12±0.02 µm(P=.001),对称性指数从 4.22±1.01 降低至 3.53±0.90 D。角膜 OCT 在术后 1 个月时在超过 80%的部位检测到 285.8±20.2 µm 平均深度的分界线。

结论

EF I-CXL 的 3 年结果显示出令人满意的 I-CXL 功能结果,增加了可见度和分界线深度,更接近上皮下标准 CXL。[J Refract Surg. 2020;36(5):286-292.]。

相似文献

1
Iontophoresis Corneal Cross-linking With Enhanced Fluence and Pulsed UV-A Light: 3-Year Clinical Results.离子导入角膜交联增强光疗:3 年临床结果。
J Refract Surg. 2020 May 1;36(5):286-292. doi: 10.3928/1081597X-20200406-02.
2
Enhanced-Fluence Pulsed-Light Iontophoresis Corneal Cross-linking: 1-Year Morphological and Clinical Results.高能量脉冲光离子导入角膜交联术:1年的形态学和临床结果
J Refract Surg. 2018 Jul 1;34(7):438-444. doi: 10.3928/1081597X-20180515-02.
3
Transepithelial Iontophoresis Versus Standard Corneal Collagen Cross-linking: 1-Year Results of a Prospective Clinical Study.经上皮离子导入法与标准角膜胶原交联术:一项前瞻性临床研究的1年结果
J Refract Surg. 2016 Oct 1;32(10):672-678. doi: 10.3928/1081597X-20160629-02.
4
Conventional and Iontophoresis Corneal Cross-Linking for Keratoconus: Efficacy and Assessment by Optical Coherence Tomography and Confocal Microscopy.圆锥角膜的传统及离子导入角膜交联术:光学相干断层扫描和共聚焦显微镜的疗效及评估
Cornea. 2017 Feb;36(2):153-162. doi: 10.1097/ICO.0000000000001062.
5
Iontophoresis CXL With and Without Epithelial Debridement Versus Standard CXL: 2-Year Clinical Results of a Prospective Clinical Study.有或无上皮清创的离子导入角膜交联术与标准角膜交联术的比较:一项前瞻性临床研究的2年临床结果
J Refract Surg. 2019 Mar 1;35(3):184-190. doi: 10.3928/1081597X-20190128-01.
6
Comparative Analysis of Safety and Efficacy of Topography-Guided Customized Cross-linking and Standard Cross-linking in the Treatment of Progressive Keratoconus.渐进性圆锥角膜行地形引导的定制交联与标准交联治疗的安全性和疗效的对比分析。
Cornea. 2021 Feb 1;40(2):188-193. doi: 10.1097/ICO.0000000000002492.
7
Standard corneal collagen crosslinking versus transepithelial iontophoresis-assisted corneal crosslinking, 24 months follow-up: randomized control trial.标准角膜胶原交联术与经上皮离子导入辅助角膜交联术的24个月随访:随机对照试验
Acta Ophthalmol. 2016 Nov;94(7):e600-e606. doi: 10.1111/aos.13032. Epub 2016 Apr 4.
8
Randomized Controlled Trial Comparing Transepithelial Corneal Cross-linking Using Iontophoresis with the Dresden Protocol in Progressive Keratoconus.离子导入诱导交联与 Dresden 方案治疗进展性圆锥角膜的随机对照临床试验
Ophthalmology. 2017 Jun;124(6):804-812. doi: 10.1016/j.ophtha.2017.01.040. Epub 2017 Mar 7.
9
Accelerated Pulsed High-Fluence Corneal Cross-Linking for Progressive Keratoconus.渐进性圆锥角膜的加速脉冲高光强角膜交联术。
Am J Ophthalmol. 2021 Jan;221:9-16. doi: 10.1016/j.ajo.2020.08.021. Epub 2020 Aug 18.
10
Corneal Cross-linking in Thin Corneas: 1-Year Results of Accelerated Contact Lens-Assisted Treatment of Keratoconus.薄角膜交联术:加速角膜接触镜辅助治疗圆锥角膜的 1 年结果。
J Refract Surg. 2019 Oct 1;35(10):642-648. doi: 10.3928/1081597X-20190903-01.

引用本文的文献

1
Progressive high-fluence epithelium-on accelerated corneal crosslinking: a novel corneal photodynamic therapy for early progressive keratoconus.逐步高能量上皮下加速角膜交联:一种用于早期进行性圆锥角膜的新型角膜光动力疗法。
Front Med (Lausanne). 2023 Aug 21;10:1198246. doi: 10.3389/fmed.2023.1198246. eCollection 2023.
2
Efficacy, Safety, and Outcomes following Accelerated and Iontophoresis Corneal Crosslinking in Progressive Keratoconus.进行性圆锥角膜加速及离子导入角膜交联术后的疗效、安全性及结果
J Clin Med. 2023 Apr 18;12(8):2931. doi: 10.3390/jcm12082931.
3
Transepithelial Enhanced Fluence Pulsed Light M Accelerated Crosslinking for Early Progressive Keratoconus with Chemically Enhanced Riboflavin Solutions and Air Room Oxygen.
经上皮增强能量脉冲光M联合化学增强核黄素溶液及空气室氧气用于早期进行性圆锥角膜的加速交联
J Clin Med. 2022 Aug 27;11(17):5039. doi: 10.3390/jcm11175039.
4
Transepithelial Iontophoresis-Assisted Cross Linking for Progressive Keratoconus: Up to 7 Years of Follow Up.经上皮离子电渗疗法辅助交联治疗进行性圆锥角膜:长达7年的随访
J Clin Med. 2022 Jan 28;11(3):678. doi: 10.3390/jcm11030678.
5
Corneal Cross-Linking: The Evolution of Treatment for Corneal Diseases.角膜交联:角膜疾病治疗的演进
Front Pharmacol. 2021 Jul 19;12:686630. doi: 10.3389/fphar.2021.686630. eCollection 2021.
6
Drug delivery to the anterior segment of the eye: A review of current and future treatment strategies.药物递送至眼前节:当前和未来治疗策略的综述。
Int J Pharm. 2021 Sep 25;607:120924. doi: 10.1016/j.ijpharm.2021.120924. Epub 2021 Jul 26.
7
Advances in the diagnosis and treatment of keratoconus.圆锥角膜诊断与治疗的进展
Ther Adv Ophthalmol. 2021 Jun 24;13:25158414211012796. doi: 10.1177/25158414211012796. eCollection 2021 Jan-Dec.
8
Chemically-Boosted Corneal Cross-Linking for the Treatment of Keratoconus through a Riboflavin 0.25% Optimized Solution with High Superoxide Anion Release.通过具有高超氧阴离子释放量的0.25%核黄素优化溶液进行化学增强角膜交联治疗圆锥角膜
J Clin Med. 2021 Mar 23;10(6):1324. doi: 10.3390/jcm10061324.
9
New perspectives in keratoconus treatment: an update on iontophoresis-assisted corneal collagen crosslinking.角膜交联术治疗圆锥角膜的新视角:离子导入辅助角膜胶原交联术的最新进展。
Int Ophthalmol. 2021 May;41(5):1909-1916. doi: 10.1007/s10792-021-01713-4. Epub 2021 Feb 16.
10
Safety and efficacy of repeated crosslinking assisted by transepithelial double-cycle iontophoresis in keratoconus progression after primary corneal crosslinking.经上皮双循环离子导入辅助重复交联在原发性角膜交联术后圆锥角膜进展中的安全性和有效性。
Eye (Lond). 2021 Nov;35(11):3020-3027. doi: 10.1038/s41433-020-01365-1. Epub 2021 Jan 7.